|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Diazoxide#Warnings]] |
| {{Diazoxide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Warnings and Precautions==
| |
| ===WARNINGS===
| |
| | |
| The antidiuretic property of diazoxide may lead to significant fluid retention, which in patients with compromised cardiac reserve, may precipitate congestive heart failure. The fluid retention will respond to conventional therapy with [[diuretics]].
| |
| | |
| It should be noted that concomitantly administered thiazides may potentiate the hyperglycemic and hyperuricemic actions of diazoxide (See DRUG INTERACTIONS andANIMAL PHARMACOLOGY AND/OR TOXICOLOGY).
| |
| | |
| Ketoacidosis and nonketotic hyperosmolar coma have been reported in patients treated with recommended doses of PROGLYCEM® usually during intercurrent illness. Prompt recognition and treatment are essential (See OVERDOSAGE), and prolonged surveillance following the acute episode is necessary because of the long drug half-life of approximately 30 hours. The occurrence of these serious events may be reduced by careful education of patients regarding the need for monitoring the urine for sugar and ketones and for prompt reporting of abnormal findings and unusual symptoms to the physician. Transient [[cataracts ]]occurred in association with hyperosmolar coma in an infant, and subsided on correction of the hyper-osmolarity. [[cataracts ]]have been observed in several animals receiving daily doses of intravenous or oral diazoxide.
| |
| | |
| The development of abnormal facial features in four children treated chronically (>4 years) with PROGLYCEM® for [[hypoglycemia ]][[hyperinsulinism ]]in the same clinic has been reported.
| |
| | |
| ===PRECAUTIONS===
| |
| | |
| ====General====
| |
| | |
| treatment with PROGLYCEM® should be initiated under close clinical supervision, with careful monitoring of blood glucose and clinical response until the patient's condition has stabilized. This usually requires several days. If not effective in two to three weeks, the drug should be discontinued.
| |
| | |
| Prolonged treatment requires regular monitoring of the urine for sugar and ketones, especially under stress conditions, with prompt reporting of any abnormalities to the physician. Additionally, blood sugar levels should be monitored periodically by the physician to determine the need for dose adjustment.
| |
| | |
| The effects of diazoxide on the hematopoietic system and the level of serum uric acid should be kept in mind; the latter should be considered particularly in patients with [[hyperuricemia]] or a history of gout.
| |
| | |
| In some patients, higher blood levels have been observed with the oral suspension than with the capsule formulation of PROGLYCEM®. Dosage should be adjusted as necessary in individual patients if changed from one formulation to the other.
| |
| | |
| Since the plasma half-life of diazoxide is prolonged in patients with impaired renal function, a reduced dosage should be considered. Serum electrolyte levels should also be evaluated for such patients.
| |
| | |
| The antihypertensive effect of other drugs may be enhanced by PROGLYCEM®, and this should be kept in mind when administering it concomitantly with antihypertensive agents.
| |
| | |
| Because of the protein binding, administration of PROGLYCEM® with coumarin or its derivatives may require reduction in the dosage of the anticoagulant, although there has been no reported evidence of excessive anticoagulant effect. In addition, PROGLYCEM® may possibly displace [[bilirubin]] from [[albumin]]; this should be kept in mind particularly when treating newborns with increased [[bilirubinemia]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PROGLYCEM (DIAZOXIDE) SUSPENSION [TEVA GLOBAL RESPIRATORY RESEARCH LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2 | publish</div>er = | date = | accessdate = 26 February 2014 }}</ref></div>
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Nonsympatholytic vasodilatory antihypertensives}}
| |
| {{Other therapeutic products}}
| |
| {{Channel openers}}
| |
| | |
| [[Category:Sulfonamides]]
| |
| [[Category:Vasodilators]]
| |
| [[Category:Potassium channel openers]]
| |
| [[Category:Benzothiadiazines]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |